Ablation therapy for liver and pancreatic cancers using Irreversible electroporation, IRE, NanoKnife

Ablation therapy for liver and pancreatic cancers using Irreversible electroporation, IRE, NanoKnife - IRE therapy for liver and pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034368

Enrollment

200

Registered

2018-10-06

Start date

2016-04-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer, Pancreatic cancer

Interventions

Therapy of single time and one day. Multiple electrode needles (2-6) are inserted in the tumor percutaneously under imaging guidance. Electric currency under high voltage provokes electroporation and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Unresectable liver and pancreatic cancers 2. No distant metastasis

Exclusion criteria

Exclusion criteria: 1. Metallic materials such as metallic stent near the tumor. 2. Arrhythmia and cardiac diseases.

Design outcomes

Primary

Measure	Time frame
Overall survival period from diagnosis to death.	—

Secondary

Measure	Time frame
Adverse events related to IRE therapy	—

Countries

Japan

Contacts

Public ContactFuminori Moriyasu

International University of Health and Welfare Sanno Hospital Center for Cancer Ablation Therapy

moriyasu@rb4.so-net.ne.jp03-3402-3151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026